

## CORRECTION



# Correction: Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells


Maria Eugenia Balañá, Leticia Labriola, Mariana Salatino, Federico Movsichoff, Giselle Peters, Eduardo H. Charreau and Patricia V. Elizalde

© The Author(s), under exclusive licence to Springer Nature Limited 2023

*Oncogene* (2023) 42:3087; <https://doi.org/10.1038/s41388-023-02821-4>

Correction to: *Oncogene* <https://doi.org/10.1038/sj.onc.1204050>, published online 17 January 2001

Following publication of this article it was noted that a Western blot (WB) in Figure 4 was inadvertently reproduced from Figure 6, panel D, of an article [1] published by the authors in the journal in 1999. The authors have provided the correct raw data corresponding to Figure 4 and the corrected figure (shown below).



The authors highlight that the findings shown in Figure 4 (C4HD cells, upper panel), which contain the inadvertent mistake, were also shown -even in a more specific manner- in Figure 5B ErbB-2 of the same article. In the experiment which results were shown in Figure 5B ErbB-2, C4HD cells cultured in MPA 10 nM were treated with ErbB-2 ASODNs or SODNs. In order to control for the levels of IGF-IR protein expression in cells transfected with ErbB-2 ASODNs or SODNs, one mg protein from cell lysates was immunoprecipitated with an IGF-IR alpha chain antibody (Santa Cruz 2C8), and immunoblotted with an IGF-IR alpha chain antibody (Santa Cruz N-20) (middle panel). Membranes shown in the middle panel were then stripped and blotted with an IGF-IR beta chain antibody (lower panel). As can be seen, the middle and lower panels of Figure 5B ErbB-2, clearly show

that silencing ErbB-2 expression in C4HD cells by using ASODNs does not affect neither IGF-IR alpha nor IGF-IR beta chains protein levels.

The authors apologize for any inconvenience caused and confirm the error in assembly does not affect the conclusions of the article.

## REFERENCE

1. Balañá M, Lupu R, Labriola L, et al. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. *Oncogene*. 1999;18:6370–9. <https://doi.org/10.1038/sj.onc.1203028>.